GILEAD SCIENCES, INC. Proceeds from Lines of Credit
GILEAD SCIENCES, INC. (GILD) reported Proceeds from Lines of Credit of $1.15 billion for the 9-month period ending 2012-09-30, per its 10-Q filed 2012-11-06.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2012-11-06
- GILEAD SCIENCES, INC. proceeds from lines of credit for the quarter ending 2012-09-30 was $148.96M.
- GILEAD SCIENCES, INC. proceeds from lines of credit for the quarter ending 2012-06-30 was $0.00.
- GILEAD SCIENCES, INC. proceeds from lines of credit for the quarter ending 2012-03-31 was $997.89M.
- GILEAD SCIENCES, INC. proceeds from lines of credit for the quarter ending 2011-12-31 was $0.00.
- GILEAD SCIENCES, INC. proceeds from lines of credit for fiscal 2011 was $0.00, a 100.00% decline from fiscal 2010.
- GILEAD SCIENCES, INC. proceeds from lines of credit for fiscal 2010 was $500.00M, a 25.00% increase from fiscal 2009.
- GILEAD SCIENCES, INC. proceeds from lines of credit for fiscal 2009 was $400.00M.
- GILEAD SCIENCES, INC. proceeds from lines of credit for fiscal 2008 was $0.00.
| Period end | Proceeds from Lines of Credit 1 month | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|---|
| 2012-09-30 | $148.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $148.96M derived: sum of 2 quarters · filed 2012-11-06 | $1.15B 10-Q · filed 2012-11-06 | $1.15B derived: sum of 4 quarters · filed 2012-11-06 | |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | $997.89M 10-Q · filed 2012-08-01 | $997.89M derived: sum of 3 quarters · filed 2012-08-01 | $997.89M derived: sum of 4 quarters · filed 2012-11-06 | |
| 2012-03-31 | $997.89M 10-Q · filed 2012-05-04 | $997.89M derived: sum of 2 quarters · filed 2012-05-04 | $997.89M derived: sum of 3 quarters · filed 2012-11-06 | $997.89M derived: sum of 4 quarters · filed 2012-11-06 | |
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $0.00 derived: sum of 2 quarters · filed 2012-11-06 | $0.00 derived: sum of 3 quarters · filed 2012-11-06 | $0.00 10-K · filed 2012-02-23 | |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $0.00 derived: sum of 2 quarters · filed 2012-11-06 | $0.00 10-Q · filed 2012-11-06 | $0.00 derived: sum of 4 quarters · filed 2012-11-06 | |
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | $0.00 10-Q · filed 2012-08-01 | $0.00 derived: sum of 3 quarters · filed 2012-08-01 | $0.00 derived: sum of 4 quarters · filed 2012-08-01 | |
| 2011-03-31 | $0.00 10-Q · filed 2012-05-04 | $0.00 derived: sum of 2 quarters · filed 2012-05-04 | $0.00 derived: sum of 3 quarters · filed 2012-05-04 | ||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $0.00 derived: sum of 2 quarters · filed 2012-02-23 | $500.00M 10-K · filed 2012-02-23 | ||
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $500.00M 10-Q · filed 2011-11-04 | |||
| 2010-06-30 | $500.00M 10-Q · filed 2011-08-05 | ||||
| 2010-05-31 | $500.00M 10-K · filed 2012-02-23 | ||||
| 2009-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $0.00 derived: sum of 2 quarters · filed 2012-02-23 | $400.00M 10-K · filed 2012-02-23 | ||
| 2009-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | $400.00M 10-Q · filed 2010-11-08 | |||
| 2009-06-30 | $400.00M 10-Q · filed 2010-08-09 | ||||
| 2009-04-30 | $400.00M 10-K · filed 2012-02-23 | ||||
| 2008-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2010-03-01 | $0.00 derived: sum of 2 quarters · filed 2010-03-01 | $0.00 10-K · filed 2010-03-01 | ||
| 2008-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2009-11-05 | $0.00 10-Q · filed 2009-11-05 | |||
| 2008-06-30 | $0.00 10-Q · filed 2009-08-05 | ||||
| 2007-12-31 | $0.00 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |